title: Outpatient cognitive behavioural therapy programme for alcohol dependence: impact of naltrexone use on outcome.
abstract: OBJECTIVE
  Cognitive-behavioural therapy (CBT) has been effectively used in the treatment of alcohol dependence. Clinical studies report that the anticraving drug naltrexone, is a useful adjunct to treatment. Currently, few data are available on the impact of adding this medication to programmes in more typical, outpatient, and rehabilitation settings. The objective of this study was to examine the impact on outcome of adding naltrexone to an established outpatient alcohol rehabilitation program which employed CBT.
  
  
  METHODS
  Fifty patients participated in an established 12-week, outpatient, 'contract'-based alcohol abstinence programme which employed CBT. They also received naltrexone 50 mg orally daily (CBT + naltrexone). Outcomes were compared with 50 historical, matched controls, all of whom participated in the same programme without an anticraving medication (CBT alone). All patients met DSM-IV criteria for alcohol dependence.
  
  
  RESULTS
  Programme attendance across the eight treatment sessions was lower in the CBT alone group (p < 0.001). Relapse to alcohol use occurred sooner and more frequently in the CBT alone group (p < 0.001). Rehabilitation programme completion at 12 weeks was 88% (CBT + naltrexone) compared with 36% for (CBT alone) (p < 0.001). Alcohol abstinence at 12 weeks was 76% (CBT + naltrexone) compared with 18% (CBT alone) (p < 0.001).
  
  
  CONCLUSIONS
  When employing the same outpatient rehabilitation programme and comparing outcomes using matched historical controls, the addition of naltrexone substantially improves programme attendance, programme completion and reported alcohol abstinence. In a typical outpatient programme, naltrexone addition was associated with significantly improved programme participation, better outcomes and was well tolerated.
authors.affiliation: Department of Psychiatry, University of Queensland, Brisbane, Australia. Gerald_Feeney@health.qld.gov.au
authors.forename: G F
authors.initials: GF
authors.lastname: Feeney
authors.forename: R M
authors.initials: RM
authors.lastname: Young
authors.forename: J P
authors.initials: JP
authors.lastname: Connor
authors.forename: J
authors.initials: J
authors.lastname: Tucker
authors.forename: A
authors.initials: A
authors.lastname: McPherson
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000188:drug therapy / Q000628:therapy*; D000553:Ambulatory Care; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D009294:Narcotics / Q000008:administration & dosage / Q000627:therapeutic use*; D015397:Program Evaluation; D016896:Treatment Outcome
chemical_list: D009294:Narcotics; D009271:Naltrexone